CPG OLIGODEOXYNUCLEOTIDE TLR9 AGONIST DV281
Advanced Non Small Cell Lung Cancer
Dynavax Technologies Corporationnucleic_acidPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
8 Active assets in the Advanced Non Small Cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
AZD9291 AstraZeneca | Phase 3 | BB |
Pemigatinib Incyte Corporation | Phase 2 | B |
ff-10832 Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 2 | CCC |
Osimertinib AstraZeneca | Phase 1 | CC |
View all 11 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →